Company news

Tiziana Life Sciences Ltd news in 2025

Tiziana Life Sciences Ltd's news releases, calls and decks from 2025, newest first.

View company

Tiziana Life Sciences Files Annual Safety Report for Intranasal Foralumab with FDA

December 30, 2025

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

December 29, 2025

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

December 19, 2025

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

December 17, 2025

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

December 17, 2025

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

December 15, 2025

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

December 15, 2025

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

December 12, 2025

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

December 2, 2025

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

November 25, 2025

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

November 13, 2025

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

November 4, 2025

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

October 29, 2025

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

September 30, 2025

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

September 25, 2025

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

September 24, 2025

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

September 15, 2025

Tiziana Life Sciences Announces Purchase of Shares by Chairman

September 5, 2025

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

August 14, 2025

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

August 11, 2025

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

July 21, 2025

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

April 2, 2025

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

March 25, 2025

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

March 17, 2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

March 14, 2025

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

March 4, 2025

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

February 27, 2025

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

February 25, 2025

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

February 21, 2025

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

February 18, 2025

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

February 10, 2025

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

January 22, 2025

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

January 21, 2025

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

January 9, 2025

Decks in 2025